Shares of Supernus Pharmaceuticals climbed in trading on April 5 after the U.S. Food and Drug Administration’s April 2 approval of the company’s non-stimulant treatment for attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age.
One year after submitting a New Drug Application for Azstarys, the U.S. Food and Drug Administration approved KemPharm’s novel ADHD drug for use in patients 6 years and older.
Supernus Pharmaceuticals Inc.’s experimental drug for attention deficit hyperactivity disorder (ADHD) met the main goal of a late-stage study in adults.
ADHD (attention-deficit/hyperactivity disorder) may be more common in elite athletes, a new research review suggests.
Supernus Pharmaceuticals Inc.’s experimental drug SPN-812 for attention deficit hyperactivity disorder met the main goal in a late-stage trial on adolescents.
There may be a strong connection between asthma and attention deficit hyperactivity disorder (ADHD) that makes people with one condition more likely to develop the other one, a recent study suggests.
Almost one year after filing a New Drug Application for an ADHD drug and less than one year after announcing it secured $200 million in financing, Ironshore Pharmaceuticals closed its doors.
Shire said it would create two distinct business units for the London-listed pharmaceutical group’s rare disease and hyperactivity medicines before deciding later this year whether to spin off the latter into a separately listed group.
Shares of Neos Therapeutics soared more than 38 percent after PDL BioPharma announced its intention to acquire the company in an all-cash deal that could total about $287 million.
Shire Plc and Shionogi & Co. Ltd. said a drug to treat ADHD in adults had met its main goal in a late-stage trial in Japan, bringing it one step closer to approval in the world’s third-biggest market for ADHD treatments.